195 related articles for article (PubMed ID: 18567857)
1. Myasthenia gravis seronegative for acetylcholine receptor antibodies.
Vincent A; Leite MI; Farrugia ME; Jacob S; Viegas S; Shiraishi H; Benveniste O; Morgan BP; Hilton-Jones D; Newsom-Davis J; Beeson D; Willcox N
Ann N Y Acad Sci; 2008; 1132():84-92. PubMed ID: 18567857
[TBL] [Abstract][Full Text] [Related]
2. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis.
Leite MI; Jacob S; Viegas S; Cossins J; Clover L; Morgan BP; Beeson D; Willcox N; Vincent A
Brain; 2008 Jul; 131(Pt 7):1940-52. PubMed ID: 18515870
[TBL] [Abstract][Full Text] [Related]
3. MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters.
Koneczny I; Cossins J; Waters P; Beeson D; Vincent A
PLoS One; 2013; 8(11):e80695. PubMed ID: 24244707
[TBL] [Abstract][Full Text] [Related]
4. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis.
Vincent A; Leite MI
Curr Opin Neurol; 2005 Oct; 18(5):519-25. PubMed ID: 16155434
[TBL] [Abstract][Full Text] [Related]
5. Two cases of thymoma-associated myasthenia gravis without antibodies to the acetylcholine receptor.
Maggi L; Andreetta F; Antozzi C; Confalonieri P; Cornelio F; Scaioli V; Mantegazza R
Neuromuscul Disord; 2008 Aug; 18(8):678-80. PubMed ID: 18657424
[TBL] [Abstract][Full Text] [Related]
6. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.
Gomez AM; Van Den Broeck J; Vrolix K; Janssen SP; Lemmens MA; Van Der Esch E; Duimel H; Frederik P; Molenaar PC; Martínez-Martínez P; De Baets MH; Losen M
Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584
[TBL] [Abstract][Full Text] [Related]
7. Passive transfer models of myasthenia gravis with muscle-specific kinase antibodies.
Verschuuren JJGM; Plomp JJ; Burden SJ; Zhang W; Fillié-Grijpma YE; Stienstra-van Es IE; Niks EH; Losen M; van der Maarel SM; Huijbers MG
Ann N Y Acad Sci; 2018 Feb; 1413(1):111-118. PubMed ID: 29356029
[TBL] [Abstract][Full Text] [Related]
8. Single-fiber electromyography in limb and facial muscles in muscle-specific kinase antibody and acetylcholine receptor antibody myasthenia gravis.
Farrugia ME; Kennett RP; Newsom-Davis J; Hilton-Jones D; Vincent A
Muscle Nerve; 2006 Apr; 33(4):568-70. PubMed ID: 16382443
[TBL] [Abstract][Full Text] [Related]
9. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.
Hoch W; McConville J; Helms S; Newsom-Davis J; Melms A; Vincent A
Nat Med; 2001 Mar; 7(3):365-8. PubMed ID: 11231638
[TBL] [Abstract][Full Text] [Related]
10. Myasthenia gravis experimentally induced with muscle-specific kinase.
Shigemoto K; Kubo S; Jie C; Hato N; Abe Y; Ueda N; Kobayashi N; Kameda K; Mominoki K; Miyazawa A; Ishigami A; Matsuda S; Maruyama N
Ann N Y Acad Sci; 2008; 1132():93-8. PubMed ID: 18096854
[TBL] [Abstract][Full Text] [Related]
11. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis.
Shiraishi H; Motomura M; Yoshimura T; Fukudome T; Fukuda T; Nakao Y; Tsujihata M; Vincent A; Eguchi K
Ann Neurol; 2005 Feb; 57(2):289-93. PubMed ID: 15668981
[TBL] [Abstract][Full Text] [Related]
12. Autoantibodies to agrin in myasthenia gravis patients.
Zhang B; Shen C; Bealmear B; Ragheb S; Xiong WC; Lewis RA; Lisak RP; Mei L
PLoS One; 2014; 9(3):e91816. PubMed ID: 24632822
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms associated with the pathogenicity of antibodies against muscle-specific kinase in myasthenia gravis.
Mori S; Shigemoto K
Autoimmun Rev; 2013 Jul; 12(9):912-7. PubMed ID: 23537506
[TBL] [Abstract][Full Text] [Related]
14. [Autoantibodies detected in acetylcholine receptor antibody-negative myasthenia gravis].
Ohta R; Motomura M
Rinsho Byori; 2014 Mar; 62(3):255-60. PubMed ID: 24800501
[TBL] [Abstract][Full Text] [Related]
15. IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients.
Koneczny I; Stevens JA; De Rosa A; Huda S; Huijbers MG; Saxena A; Maestri M; Lazaridis K; Zisimopoulou P; Tzartos S; Verschuuren J; van der Maarel SM; van Damme P; De Baets MH; Molenaar PC; Vincent A; Ricciardi R; Martinez-Martinez P; Losen M
J Autoimmun; 2017 Feb; 77():104-115. PubMed ID: 27965060
[TBL] [Abstract][Full Text] [Related]
16. Effect of sera from AChR-antibody negative myasthenia gravis patients on AChR and MuSK in cell cultures.
Farrugia ME; Bonifati DM; Clover L; Cossins J; Beeson D; Vincent A
J Neuroimmunol; 2007 Apr; 185(1-2):136-44. PubMed ID: 17335909
[TBL] [Abstract][Full Text] [Related]
17. Myopathic changes detected by quantitative electromyography in patients with MuSK and AChR positive myasthenia gravis.
Nikolic A; Basta I; Stojanovic VR; Stevic Z; Peric S; Lavrnic D
J Clin Neurosci; 2016 May; 27():126-9. PubMed ID: 26778359
[TBL] [Abstract][Full Text] [Related]
18. Clinical phenotype of muscle-specific tyrosine kinase-antibody-positive myasthenia gravis.
Wolfe GI; Oh SJ
Ann N Y Acad Sci; 2008; 1132():71-5. PubMed ID: 18567855
[TBL] [Abstract][Full Text] [Related]
19. Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology.
Fichtner ML; Jiang R; Bourke A; Nowak RJ; O'Connor KC
Front Immunol; 2020; 11():776. PubMed ID: 32547535
[TBL] [Abstract][Full Text] [Related]
20. Antibodies identified by cell-based assays in myasthenia gravis and associated diseases.
Vincent A; Waters P; Leite MI; Jacobson L; Koneczny I; Cossins J; Beeson D
Ann N Y Acad Sci; 2012 Dec; 1274():92-8. PubMed ID: 23252902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
